TY - JOUR
T1 - Phase II study of Rituximab combined with THP-COP as first-line therapy for patients younger than 70 years with diffuse large B cell lymphoma
AU - Hara, Takeshi
AU - Tsurumi, Hisashi
AU - Goto, Naoe
AU - Kitagawa, Jun Ichi
AU - Kanemura, Nobuhiro
AU - Yoshikawa, Takeshi
AU - Kasahara, Senji
AU - Goto, Hideko
AU - Fukuno, Kenji
AU - Yamada, Toshiki
AU - Sawada, Michio
AU - Yasuda, Ichiro
AU - Katsumura, Naoki
AU - Takahashi, Takeshi
AU - Takami, Tsuyoshi
AU - Moriwaki, Hisataka
PY - 2010/1
Y1 - 2010/1
N2 - Introduction: We previously described the effectiveness of the THP-COP regimen comprising cyclophosphamide, pirarubicin (tetrahydropyranyl adriamycin; THP), vincristine and prednisolone in patients with diffuse large B-cell lymphoma (DLBCL). The anthracycline drug THP was apparently less cardiotoxic than doxorubicin. However, that study was completed before rituximab was introduced into clinical practice. We conducted a phase II study to determine the effectiveness of a regimen incorporating rituximab (R-THP-COP) against DLBCL. Patients: Six to 8 courses of the regimen were administered every 2 weeks in 48 patients who were younger than 70 years. Results: The complete remission rate was 92%, the 3-year overall survival rate was 83% and 3-year progression free survival rate was 74%. No deaths were associated with the treatment regimen. Conclusion: We conclude that R-THP-COP regimen is very effective against DLBCL. The results of our study urge randomized trials of R-CHOP and R-THP-COP among patients with CD20+ DLBCL.
AB - Introduction: We previously described the effectiveness of the THP-COP regimen comprising cyclophosphamide, pirarubicin (tetrahydropyranyl adriamycin; THP), vincristine and prednisolone in patients with diffuse large B-cell lymphoma (DLBCL). The anthracycline drug THP was apparently less cardiotoxic than doxorubicin. However, that study was completed before rituximab was introduced into clinical practice. We conducted a phase II study to determine the effectiveness of a regimen incorporating rituximab (R-THP-COP) against DLBCL. Patients: Six to 8 courses of the regimen were administered every 2 weeks in 48 patients who were younger than 70 years. Results: The complete remission rate was 92%, the 3-year overall survival rate was 83% and 3-year progression free survival rate was 74%. No deaths were associated with the treatment regimen. Conclusion: We conclude that R-THP-COP regimen is very effective against DLBCL. The results of our study urge randomized trials of R-CHOP and R-THP-COP among patients with CD20+ DLBCL.
UR - http://www.scopus.com/inward/record.url?scp=71449091635&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=71449091635&partnerID=8YFLogxK
U2 - 10.1007/s00432-009-0637-x
DO - 10.1007/s00432-009-0637-x
M3 - Article
C2 - 19590893
AN - SCOPUS:71449091635
SN - 0171-5216
VL - 136
SP - 65
EP - 70
JO - Journal of Cancer Research and Clinical Oncology
JF - Journal of Cancer Research and Clinical Oncology
IS - 1
ER -
